Moderna’s Sales Miss Forecasts by 20%. Pfizer Is Taking the U.S. Vaccine Market.

2 years ago 245

Moderna shares plunged 12.3% successful premarket trading connected Thursday aft income of the company’s Covid-19 vaccine fell abbreviated of Wall Street analysts’ estimates by much than a cardinal dollars.

The institution reported full gross of $5 cardinal for the 3rd 4th of the year, 20% abbreviated of the FactSet expert statement estimation of $6.2 billion. Spikevax, Moderna‘s (ticker: MRNA) Covid-19 vaccine, is the company’s lone product.

The...

Read Entire Article

Moderna’s Sales Miss Forecasts by 20%. Pfizer Is Taking the U.S. Vaccine Market.

Related

How we use Guest Posting as a Powerful Branding Tool

J.P. Morgan’s 2 Stock Picks With Over 80% Upside Potential

A 27-year-old truck driver just became Robinhood’s first big...

Rivian’s Stock Slide Deepens as Operating Chief Steps Down

Trending

Popular

Akamai adds new capabilities and tools for developers

Good News, Bad News on Alzheimer's Vaccine

Muḥammad ibn Mūsā al-Khwārizmī

Southern Baptist Convention Elects Ed Litton as New Presiden...

AHA News: U.S. Appears to Lose Ground in Controlling High Bl...